Gubra concludes the research agreement with UK Biotech
Today, Gubra announces the finalization of its two-year explorative research agreement with Silence Therapeutics PLC that was signed in early 2022. The collaboration concerned early target discovery of RNAi therapies for liver diseases.
In collaboration with Silence Therapeutics, we have explored potential novel liver-targets for diseases with an unmet medical need. We have had a great collaboration with Silence Therapeutics, and both parties have completed the planned activities according to the research plan. Today, we have jointly decided not to further pursue any research activities under this collaboration and consequently Gubra does not expect future income from this collaboration.